MRAs and Low-Ceiling Diuretics Drive Potassium Shifts in Elderly Polypharmacy
This dual-cohort real-world analysis ranks the relative potassium impact of common cardiorenal drug classes across chronic kidney disease stages in older, multi-medicated patients, informing which agents warrant the closest monitoring.
Potassium imbalances are common in older patients on multiple drugs.
Potassium imbalances in older adults on multiple medications can lead to serious health implications. Hypokalemia occurred in 28.4% and hyperkalemia in 20.3% of patients; MRAs and diuretics notably affected potassium levels depending on CKD stage. Renal function and specific drug classes should be carefully monitored to prevent adverse potassium level changes in older patients. The study highlights risks of polypharmacy in older adults with CKD. Monitoring potassium levels in multi-medicated older adults is crucial, particularly when using MRAs and diuretics.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Laurentius T, Al-Musawer E, Schmitz K, Bollheimer C, Wozniak J, Graeff V, Kriegisch-Stumpf A, Knüppel-Ruppert A, Dormann H, Stingl JC, Just KS
Citation:Laurentius T, Al-Musawer E, Schmitz K, et al. Influence of drugs on blood potassium levels in older, multi-medicated patients - results of two cohort studies focusing on adverse drug reactions. BMC geriatrics. 2026;26(1). doi:10.1186/s12877-026-07899-5
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.